Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Imaging Features of Nodules: What Makes a Lung Nodule High Risk for Cancer?
Author
Howard (Jack) West, MD

As you might suspect, there are features of different spolitary pulmonary nodules (SPNs) that makes us more or less suspicious for cancer. The first is the size of the nodule. Looking at multiple series of SPNs, the likelihood of cancer among nodules that measured under 5 mm is generally in the 0-1% range. Nodules in the 5-10 mm range have been found to be cancer in up to about about 28% of cases, with most studies showing the risk of cancer in this range to be one in four or five. SPNs in the 1-2 cm range are found to be cancer about 40-50% of the time, and beyond that, the risk is up to about 60-80%. But even among the larger ones, that go from being a nodule to a mass (3 cm cutoff), the likelihood of cancer isn't 100%, and there are many things that turn out to be infection or inflammation or another benign cause.

In general, smooth borders for a nodule are somewhat reassuring, especially solitary ones. Metastases from other places tend to be smooth and toward the outside of the lung, so that's an exception of when smooth edges can be a bad thing. The most common shape of a primary lung cancer is spiculated, or stellate, with little projections, so it has irregular borders.

Then there's the issue of the density of the nodule. Solid nodules appear as pretty uniformly white on the CT (example in my prior post), while those that are just hazy clouds are called ground-glass opacities, or GGOs. In between is a nodule that appears to have areas of non-solid haziness next to other areas that are solid. These are called, coincidently, semi-solid nodules or opacities.

GGo and semi-solid nodule

(Click to enlarge image -- but it still may be hard to see the haze around the nodule on the right image)

We're still learning more about what these characteristics signify. Some of the I-ELCAP work has suggested that the patients with the highest risk of a nodule being cancer are the ones with a semi-solid nodule. Others have shown that pure GGOs are more likely to be cancer, up to about 2/3 or 3/4. But as you can get a sense from the images, these aren't the most rigid definitions. When I hear GGO, I think that this could be a pneumonia (often described as consolidation, another term for similar haziness that is more dense and obscures the underlying blood vessels in a way that a GGO shouldn't), but it's also a classic descriptor of a BAC cancer. Many of us think that the GGO portion corresponds to a non-invasive or "pure BAC" component, while the solid part of a semi-solid nodule often corresponds to an invasive portion of an adenocarcinoma that has some non-invasive BAC features around it (this spectrum that includes some areas of invasive BAC and other areas of invasive adenocarcinoma is described in a prior post). The other thing that we tend to see is that the level of metabolic uptake (the standard uptake value, or SUV) increases when you move from a higher percentage of GGO (or, under the microscope, non-invasive BAC) to a more solid nodule (more invasive cancer). This shouldn't be surprising because PET scans identify concentrations of cells that take up labeled sugar molecules, and a solid nodule is a denser collection of cells than an air-filled GGO.

Enough for now: next we'll move to growth patterns and doubling times.

Next Previous link

Previous PostNext Post

Related Content

Article
Advance directives are a powerful way to take control of healthcare choices. These documents allow you to outline preferences for medical care and specify end-of-life wishes. These documents can also be a way to appoint loved ones who you would like to help with these decisions, such as a healthcare proxy (someone to make decisions on your behalf, if you cannot). As cancer treatments can involve aggressive treatments and/or complex medical management, having advance directives ensures that your desires regarding treatment options and end-of-life care are clearly communicated. 
Image
2024-25 patient perspectives header
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial.  We want to hear from you!
Image
Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón
Video
¡El vídeo completo bajo demanda está disponible para verlo!

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on